agilon health Files 8-K on Operations & Financial Condition

TL;DR

**AGL filed an 8-K on Jan 5, 2024, updating on operations and financials.**

AI Summary

agilon health, inc. filed an 8-K on January 5, 2024, to report on its results of operations and financial condition, as well as to make a Regulation FD disclosure. This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. For shareholders, this matters because it provides transparency into the company's recent financial activities, potentially influencing stock valuation and investment decisions.

Why It Matters

This filing provides investors with an update on agilon health's financial performance, which is essential for assessing the company's health and making informed investment decisions.

Risk Assessment

Risk Level: low — This 8-K is a routine disclosure of financial information and does not inherently present new risks, but rather provides data for risk assessment.

Analyst Insight

A smart investor would review the detailed financial information provided in the full 8-K filing to understand the specific results of operations and financial condition, as this summary only indicates the filing's purpose.

Key Numbers

• January 5, 2024 — Date of Report (Indicates the specific date of the earliest event reported in the filing.)
• 001-40332 — Commission File Number (Unique identifier for agilon health, inc. with the SEC.)
• $0.01 — Par value per share (The nominal value assigned to each share of common stock.)

Key Players & Entities

• agilon health, inc. (company) — the registrant filing the 8-K
• January 5, 2024 (date) — date of earliest event reported and filing date
• Delaware (company) — state of incorporation for agilon health, inc.
• $0.01 (dollar_amount) — par value per share of common stock
• AGL (company) — trading symbol for agilon health, inc.

FAQ

Key Financial Figures

• $0.01 — ch registered Common stock, par value $0.01 per share AGL The New York Stock Exchan

Filing Documents

• agl-20240105.htm (8-K) — 30KB
• agl-8kx01052024xex991.htm (EX-99.1) — 48KB
• agl-8kx01052024xex992.htm (EX-99.2) — 21KB
• agl-8kx01052024xex992001.jpg (GRAPHIC) — 39KB
• agl-8kx01052024xex992002.jpg (GRAPHIC) — 333KB
• agl-8kx01052024xex992003.jpg (GRAPHIC) — 117KB
• agl-8kx01052024xex992004.jpg (GRAPHIC) — 83KB
• agl-8kx01052024xex992005.jpg (GRAPHIC) — 81KB
• agl-8kx01052024xex992006.jpg (GRAPHIC) — 100KB
• agl-8kx01052024xex992007.jpg (GRAPHIC) — 108KB
• agl-8kx01052024xex992008.jpg (GRAPHIC) — 95KB
• agl-8kx01052024xex992009.jpg (GRAPHIC) — 105KB
• agl-8kx01052024xex992010.jpg (GRAPHIC) — 85KB
• agl-8kx01052024xex992011.jpg (GRAPHIC) — 66KB
• agl-8kx01052024xex992012.jpg (GRAPHIC) — 86KB
• image_0.jpg (GRAPHIC) — 9KB
• 0001628280-24-000516.txt ( ) — 2097KB
• agl-20240105.xsd (EX-101.SCH) — 2KB
• agl-20240105_lab.xml (EX-101.LAB) — 25KB
• agl-20240105_pre.xml (EX-101.PRE) — 24KB
• agl-20240105_htm.xml (XML) — 3KB

02 Results of Operations and Financial Condition

Item 2.02 Results of Operations and Financial Condition. On January 5, 2024, agilon health, inc. ("agilon health") issued a press release updating its full year 2023 guidance, providing its initial outlook for 2024 and withdrawing its 2026 outlook. A copy of the press release is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. agilon health will host a conference call on Friday, January 5, 2024 at 8:00 AM Eastern Time with management remarks and a question and answer session. The conference call can be accessed by dialing (800) 590-8290 for U.S. participants and +1 (240) 690-8800 for international participants and referencing participant code AGL2024. A simultaneous webcast may be accessed by visiting the "Events & Presentations" section of agilon's Investor Relations website at https://investors.agilonhealth.com. A replay of the call will be available via webcast for on-demand listening shortly after the completion of the call. A copy of the investor presentation that will be used during the conference call is furnished herewith as Exhibit 99.2 and is incorporated by reference herein. The information set forth in Items 2.02 and 7.01 of this Current Report on Form 8-K and the related information in Exhibit 99.1 and Exhibit 99.2 attached hereto is being furnished herewith, and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section and shall not be incorporated by reference in any filing with, the Securities and Exchange Commission under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference therein.

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated January 5, 2024. 99.2 Investor Presentation dated January 5, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. agilon health, inc. Date: January 5, 2024 By: /s/ TIMOTHY S. BENSLEY Timothy S. Bensley Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR